Review reveals functionalized lipid nanoparticles effectively cross the blood-brain barrier to target gliomas, suggesting promising new treatment avenues.
Gliomas, particularly glioblastomas, are brain tumors characterized by aggressive growth, high recurrence rates, and a median 5-year survival rate of ~5%. Treatment of brain tissue is highly restricted due to the blood-brain barrier’s (BBB) selective permeability, which makes gliomas incredibly difficult to target. In recent years, there have been many developments in the use of lipid nanoparticles (LNPs) as drug delivery systems. Specifically, functionalized LNPs have shown promise in treating gliomas due to their ability to cross the blood-brain barrier. This review presents the surface-modified LNPs designed for glioma treatment that have demonstrated efficacy in in vivo animal studies. Presented here are LNPs loaded with chemotherapy and functionalized with transferrin, lactoferrin, Angiopep-2, ApoE, and cell-penetrating peptides that demonstrate a promising ability to treat gliomas.
No takes yet. Share an insight, caveat, or question.
Jeffrey Huang (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: